Cargando…
Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine
Although promising, dendritic cell (DC) vaccines still provide limited clinical benefits, mainly due to the immunosuppressive tumor microenvironment (TME) and the lack of tumor-associated antigens (TAAs). Oncolytic virus therapy is an ideal strategy to overcome immunosuppression and expose TAAs; the...
Autores principales: | Dan, Jia, Cai, Jing, Zhong, Yingqian, Wang, Chaoqun, Huang, Shanyu, Zeng, Ying, Fan, Zhen, Xu, Cuiying, Hu, Linyi, Zhang, Jiayu, Hu, Jun, Liu, Ying, Su, Xingwen, Zhu, Wenbo, Yan, Guangmei, Liang, Jiankai, Lin, Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591054/ https://www.ncbi.nlm.nih.gov/pubmed/37820722 http://dx.doi.org/10.1016/j.xcrm.2023.101229 |
Ejemplares similares
-
Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade
por: Liu, Yang, et al.
Publicado: (2020) -
Lonidamine potentiates the oncolytic efficiency of M1 virus independent of hexokinase 2 but via inhibition of antiviral immunity
por: Cai, Jing, et al.
Publicado: (2020) -
Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors
por: Song, Deli, et al.
Publicado: (2022) -
A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1
por: Li, Kai, et al.
Publicado: (2016) -
DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage
por: Xiao, Xiao, et al.
Publicado: (2018)